FDA to review Moderna mRNA flu vaccine on June 18
The FDA will convene an expert panel on June 18 to evaluate Moderna's mRNA-based flu vaccine. A final decision on the experimental shot is expected by August 5.
Xurve View
Insights:
Xurve View
The United States FDA will convene an expert panel to review the seasonal influenza vaccine from Moderna. The agency previously rejected the mRNA-based shot in February but reversed course after discussions with the company. A final approval decision is expected by August 5.
